亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders

焦虑 惊恐障碍 广场恐怖症 医学 精神科 耐受性 随机对照试验 科克伦图书馆 荟萃分析 安慰剂 认知疗法 认知 临床心理学 心理学 不利影响 内科学 替代医学 病理
作者
Rasmita Ori,Taryn Amos,Hanna Bergman,Karla Soares‐Weiser,Jonathan Ipser,Dan Joseph Stein
出处
期刊:The Cochrane library [Elsevier BV]
卷期号:2015 (5): CD007803-CD007803 被引量:115
标识
DOI:10.1002/14651858.cd007803.pub2
摘要

BACKGROUND: A significant number of patients who suffer with anxiety and related disorders (that is post-traumatic stress disorder (PTSD), social anxiety disorder (SAnD), panic disorder with or without agoraphobia (PD), specific phobia (SPh) and obsessive compulsive disorder (OCD)) fail to respond optimally to first-line treatment with medication or cognitive and behavioural therapies. The addition of d-cycloserine (DCS) to cognitive and behavioural therapies may improve treatment response by impacting the glutamatergic system. This systematic review aimed to investigate the effects of adding DCS to cognitive and behavioural therapies by synthesising data from relevant randomised controlled trials and following the guidelines recommended by Cochrane. OBJECTIVES: To assess the effect of DCS augmentation of cognitive and behavioural therapies compared to placebo augmentation of cognitive and behavioural therapies in the treatment of anxiety and related disorders. Additionally, to assess the efficacy and tolerability of DCS across different anxiety and related disorders. SEARCH METHODS: This review fully incorporates studies identified from a search of the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR) to 12 March 2015. This register includes relevant randomised controlled trials (RCTs) from: the Cochrane Library (all years), EMBASE (1974 to date), MEDLINE (1950 to date), PsycINFO (1967 to date), the World Health Organization's trials portal (ICTRP) and ClinicalTrials.gov . Reference lists from previous meta-analyses and reports of RCTs were also checked. No restrictions were placed on language, setting, date or publication status. SELECTION CRITERIA: All RCTs of DCS augmentation of cognitive and behavioural therapies versus placebo augmentation of cognitive and behavioural therapies for anxiety and related disorders were included. DATA COLLECTION AND ANALYSIS: Two authors (RO and TA) independently assessed RCTs for eligibility and inclusion, extracted outcomes and risk of bias data and entered these into a customised extraction form. Investigators were contacted to obtain missing data. In addition, data entry and analysis were performed by two review authors (KSW and HB). MAIN RESULTS: Twenty-one published RCTs, with 788 participants in outpatient settings, were included in the review. Sixteen studies had an age range of 18 to 75 years, while four investigated paediatric populations aged 8 to 17 years and one included children, adolescents and adults. The 21 RCTs investigated OCD (number of RCTs (N) = 6), PTSD (N = 5), SAnD (N = 5), SPh (N = 3) and PD (N = 2). Most information from the studies was rated as having either low risk or unclear risk of bias.There was no evidence of a difference between DCS augmentation of cognitive and behavioural therapies and placebo augmentation of cognitive and behavioural therapies for the treatment of anxiety and related disorders in adults at the endpoint (treatment responders, N = 9, risk ratio (RR) 1.10; 95% confidence interval (CI) 0.89 to 1.34; number of participants (n) = 449; low quality evidence) and between 1 and 12 months follow-up (N = 7, RR 1.08; 95% CI 0.90 to 1.31; n = 383). DCS augmentation of cognitive and behavioural therapies was not superior to placebo augmentation of cognitive and behavioural therapies for children and adolescents, both at the endpoint (N = 4, RR 1.01; 95% CI 0.78 to 1.31; n = 121; low quality evidence) and between 3 and 12 months follow-up (N = 3, RR 0.86; 95% CI 0.67 to 1.09; n = 91).There was no evidence of a difference in treatment acceptability for DCS augmentation of cognitive and behavioural therapies compared with placebo augmentation of cognitive and behavioural therapies in adults (N = 16, RR 0.88; 95% CI 0.61 to 1.25; n = 740), nor in children and adolescents (N = 4, RR 0.90; 95% CI 0.17 to 4.69; n = 131). These conclusions were based on moderate quality evidence for adults, and very low quality evidence for children and adolescents. Although the observed difference was small, it is noteworthy that there was a high efficacy of exposure-based therapies alone in the included trials. Due to the limited number of studies, subgroup analysis of moderating factors for clinical and methodological effect could not take place. AUTHORS' CONCLUSIONS: This review found no evidence of a difference between DCS augmentation of cognitive and behavioural therapies and placebo augmentation of cognitive and behavioural therapies for treating anxiety and related disorders in children, adolescents and adults. These findings are based on low quality evidence from heterogenous studies with small sample sizes and incomplete data for clinical response, which precludes us from drawing conclusions on the use of DCS augmentation of cognitive and behavioural therapies at this stage. Given there is some promising preliminary data from individual studies, further research is necessary to assess DCS compared with placebo augmentation of cognitive and behavioural therapies, and determine mechanisms of action as well as magnitude of effect in anxiety and related disorders.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
3秒前
maki完成签到,获得积分10
6秒前
q2026完成签到 ,获得积分20
6秒前
123完成签到,获得积分10
7秒前
缓慢的秋荷完成签到,获得积分10
7秒前
Laluna的应助被suicone采纳,获得10
8秒前
巨型肥猫发布了新的文献求助10
8秒前
12秒前
12秒前
肉袒牵洋完成签到 ,获得积分10
15秒前
欢喜的不尤完成签到,获得积分10
16秒前
神勇的筝发布了新的文献求助30
17秒前
bkagyin的应助被兴奋小蚂蚁采纳,获得10
18秒前
18秒前
19秒前
20秒前
whs关闭了whs的文献求助
22秒前
DOC_XIONG的应助被涵泽采纳,获得10
27秒前
28秒前
yangyang完成签到 ,获得积分10
28秒前
沉静代秋完成签到,获得积分20
28秒前
sss完成签到 ,获得积分10
29秒前
可靠的公爵熊完成签到,获得积分10
32秒前
三四月完成签到 ,获得积分10
33秒前
文静楷瑞完成签到,获得积分10
34秒前
花痴的善若完成签到,获得积分10
35秒前
zzl完成签到 ,获得积分10
35秒前
跳跃的乐曲完成签到,获得积分10
36秒前
vanilla完成签到,获得积分10
36秒前
兴奋小蚂蚁完成签到,获得积分10
37秒前
咕噜咕噜完成签到 ,获得积分10
38秒前
41秒前
乐乐的应助被开心的中心采纳,获得10
43秒前
Anserbe完成签到,获得积分10
43秒前
43秒前
43秒前
45秒前
orixero的应助被科研通管家采纳,获得10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778